Repligen | RGEN - Pre Tax Profit


Repligen reported $17.11M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Agilent USD 442M 1000K Sep/2025
Align Technology USD 176.6M 81.86M Dec/2025
Bio Techne USD 84.99M 107.85M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Bruker USD -72.6M 73.1M Sep/2025
Charles River Laboratories USD 170.03M 98.62M Sep/2025
Danaher USD 1.24B 138M Mar/2026
Dentsply International USD -230M 77M Sep/2025
General Electric Aerospace USD 2.2B 654M Mar/2026
Henry Schein USD 137M 16M Sep/2025
Illumina USD 220M 86M Sep/2025
IQVIA Holdings USD 537M 5.62B Dec/2025
Mettler Toledo International USD 269.24M 20.58M Sep/2025
Myriad Genetics USD 4.6M 3.4M Dec/2025
OraSure Technologies USD -18.43M 5.14M Dec/2025
Pacific Biosciences Of California USD -40.17M 2.55M Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Repligen USD 17.11M 10.25M Sep/2025
Revvity USD 55.68M 115.97M Sep/2025
Standard Biotools USD -22.03M 10.87M Dec/2025
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
Waters USD 170.12M 7.57M Sep/2025
West Pharmaceutical Services USD 161.5M 8.6M Dec/2025